The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalculus Vct Regulatory News (CLC)

Share Price Information for Calculus Vct (CLC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 60.00
Bid: 50.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 20.00 (40.00%)
Open: 60.00
High: 60.00
Low: 50.00
Prev. Close: 60.00
CLC Live PriceLast checked at -
Calculus VCT is an Investment Trust

To invest primarily in a diverse portfolio of VCT qualifying UK growth companies whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of General Meeting

29 Mar 2012 07:00

RNS Number : 3080A
Clinical Computing PLC
29 March 2012
 



CLINICAL COMPUTING PLC

PROPOSED CANCELLATION OF AIM ADMISSION AND NOTICE OF GENERAL MEETING

 

Clinical Computing Plc ("the Company"), the international developer of clinical information systems for the healthcare market and developer of programme management software, announces its intention to seek Shareholder approval for the cancellation of admission of Shares to trading on AIM. The Company trades through four operating subsidiaries: Clinical Computing UK Limited in the United Kingdom and Europe, Clinical Computing Inc. in the United States, Clinical Computing Pty Limited in Australia and Hydra Management Limited ("Hydra") in the United Kingdom.

 

 

An explanatory circular has today been posted to Shareholders setting out the background to and reasons for the Cancellation, why the Directors believe the Cancellation is in the best interests of the Company and its Shareholders and why they recommend that Shareholders vote in favour of the Resolution as they intend to do in respect of their own current beneficial holdings of, in aggregate, 9,710,829 Ordinary Shares, representing 8.75 per cent. of the current issued share capital of the Company. Additionally, the Company has received irrevocable undertakings from certain Shareholders to vote in favour of the Resolution, which, when taken together with the Directors' holdings, amount to 65,562,076 Ordinary Shares, representing approximately 59.13 per cent. of the current issued share capital of the Company.

 

 

A General Meeting of the Company will be held at IP City Centre, 1 Bath Street, Ipswich, IP2 8SD at 16:00 on 23 April 2012 at which Cancellation Resolution will be proposed to approve the Cancellation. A notice convening the General Meeting is set out in the circular.

 

 

 

Contacts:

Joe Marlovits, Chief Executive

Clinical Computing Plc

www.ccl.com

 

01473 694770

James Caithie

Cairn Financial Advisers LLP - Nominated Adviser

020 7148 7900

 

 

The Cancellation

 

Reasons for the Cancellation

The principal reasons for the Admission of the Ordinary Shares to trading on AIM have been to provide the Company with the ability to access capital in order to fund its strategy and to use its Ordinary Shares for acquisitions. Having recently undertaken a review of both the advantages and disadvantages of maintaining Admission of the Ordinary Shares to trading on AIM, the Directors have concluded that it is no longer in the best interests of the Company or its Shareholders to maintain the Admission. In reaching this conclusion, the Directors have taken the following factors into account:

 

A. given the overall market conditions for small listed companies, the Directors are of the opinion that it is (and will likely continue to be) difficult for the Company to attract meaningful equity investment through its listing on AIM;

 

 

B. the AIM listing of the Ordinary Shares does not, in itself, offer investors increased liquidity or marketability of the Shares and there is no opportunity to trade in meaningful volumes or with any frequency. With little trading volume, the Share price can move up or down significantly following trades of small numbers of Shares; and

 

C. the Directors estimate that annual direct and indirect costs of the AIM listing of the Ordinary Shares are at least £80,000. This estimate includes listing expenses and advisory, legal and audit fees but excludes any costs associated with the considerable amount of senior executive time which is also spent dealing with the issues related to maintaining the Admission on AIM.

 

Pursuant to AIM Rule 41, the Delisting can only be effected by the Company after securing a resolution of Shareholders in a general meeting passed by a requisite majority being not less than 75 per cent. of the votes cast by Shareholders (in person or by proxy). Under the AIM Rules the Delisting can only take place after the expiration of a period of twenty Business Days from the date on which notice of the Delisting is given. In addition, a period of at least five Business Days following the Shareholder approval of the Delisting is required before the Delisting may be put into effect.

 

The Company has notified the London Stock Exchange of the proposed Delisting. In the event that Shareholders approve the Resolution approving the Delisting, it is anticipated that the trading in the Ordinary Shares on AIM will cease at close of business on 30 April 2012 with the Delisting taking effect at 7.00am on 1 May 2012.

 

Shareholders should note however that the Company will nevertheless remain subject to the provisions of the City Code on Takeovers and Mergers for a period of 10 years from the Delisting.

 

Effect of Delisting

The principal effect of the Delisting is that cancellation in the trading of the Ordinary Shares on AIM may reduce the liquidity and marketability of Shares.

 

JP Jenkins provides companies which are unlisted and unquoted with a facility enabling existing and prospective shareholders to deal in their shares.

 

It is intended that Shareholders will be able to trade their Shares via the JP Jenkins share matching facility for companies. The Directors believe JP Jenkins provides a cost effective mechanism to buy or sell shares. Shareholders can use their existing stockbroker should they have one. Shareholders will need to instruct their existing stockbroker with a limit order who in turn will contact JP Jenkins to place the limit order on their behalf. Once the limit order has been executed, the Shareholder will receive a contract note from their stockbroker.

 

Should a Shareholder not have a stockbroker they can still use the services of JP Jenkins.

 

CREST

The Company's Shares will remain eligible for settlement in CREST. Accordingly, Shareholders will continue to be able to hold their Shares in CREST after Delisting.

 

 

Recommendation

For the reasons set out above, the Directors believe that the proposed Delisting is in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors unanimously recommend that Shareholders vote in favour of the Resolution approving the Delisting as they have undertaken so to do in respect of their own current beneficial holdings of, in aggregate, 9,710,829 Ordinary Shares, representing 8.75 per cent. of the current issued share capital of the Company.

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 

Latest time and date for receipt of Forms of Proxy 16:00 on 21 April 2012

 

General Meeting 16:00 on 23 April 2012

 

Last day of dealings in Ordinary Shares on AIM 30 April 2012

Delisting takes effect 7:00 a.m. on 1 May 2012

 

All of the times referred to are London time.

 

All of these times and dates are subject to change at the Company's discretion. In the event of any change, the revised times and dates will be notified to Shareholders by an announcement through a Regulatory Information Service.

 

The Cancellation requires the approval of not less than 75% of the votes cast by Shareholders at the General Meeting.

 

 

DEFINITIONS

The following definitions apply throughout this document unless the context requires otherwise:

 

 

 

"Admission" the admission of the Ordinary Shares to trading on AIM;

 

"AIM" the AIM market operated by the London Stock Exchange;

 

"Board" or "Directors" the board of directors of the Company

 

"Company" or a company registered in England and Wales with company "Clinical Computing Plc" number 1429835 and whose registered office is at 1P City,

1 Bath Street, Ipswich IP2 8SD.

 

"CREST" a relevant system (as defined in the CREST Regulations) in respect of which Euroclear is the Operator (as defined in the CREST Regulations);

 

"Delisting" the proposed cancellation of admission of the Ordinary Shares to trading on AIM;

 

"Form of Proxy" the form of proxy to be used by Shareholders in connection with the General Meeting;

 

"General Meeting" the general meeting of the Company convened for 16:00 on 23 April 2012 (or any adjournment thereof), notice of which is set out at the end of this document;

 

"JP Jenkins" means the trading division of Rivington Stockbrokers which is licensed by the Isle of Man Financial Supervision Commission whose registered office is at 4th Floor, 39 Athol Street, Douglas, Isle of Man IM1 1LA;

 

"London Stock London Stock Exchange plc;

Exchange"

 

"Ordinary Shares" ordinary shares of 1 pence each in the capital of the Company;

 

"Regulatory Information any of the services approved by the London Stock Exchange Service" plc for the distribution of AIM announcements and included

 within the list maintained on the website of the London Stock Exchange;

 

"Resolution" the resolution to be proposed at the General Meeting;

 

"Shareholders" holders of Ordinary Shares and the term "Shareholder" shall mean any one of them;

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOESELFWAFESEDD
Date   Source Headline
24th Apr 20244:49 pmRNSTransaction in Own Shares
5th Apr 20242:54 pmRNSIssue of Equity - 5 April 2024
22nd Feb 20244:38 pmRNSDirectorship Change
15th Feb 202411:53 amRNSIssue of Equity - 15 February 2024
1st Feb 20244:38 pmRNSNet Asset Value - 31 December 2023
10th Jan 20245:27 pmRNSTransaction in Own Shares
21st Dec 202310:08 amRNSDirectorate Change
15th Dec 20233:25 pmRNSIssue of Equity - 15 December 2023
20th Nov 20232:11 pmRNSSeptember 2023 NAV Announcement
13th Nov 20234:46 pmRNSHalf-year Report
22nd Sep 20231:03 pmRNSPublication of a Prospectus
21st Sep 20233:51 pmRNSAppointment of Auditor
7th Sep 20234:57 pmRNSTransaction in Own Shares
30th Aug 202311:28 amRNSStatement re Intention to Raise
25th Aug 20231:19 pmRNSIssue of Equity
21st Aug 20233:25 pmRNSAGM and GM Statement
21st Jul 202312:13 pmRNSIssue of Equity and Total Voting Rights
17th Jul 20233:04 pmRNSPublication of Circular and Notice of GM
3rd Jul 20235:43 pmRNSMay 2023 NAV Announcement
30th Jun 20232:15 pmRNSAnnual Financial Report & Change in Year-End date
5th Apr 20234:52 pmRNSIssue of Equity
5th Apr 20232:40 pmRNSIssue of Equity
15th Mar 20232:45 pmRNSIssue of Equity
9th Mar 20235:31 pmRNSTransaction in Own Shares
9th Mar 20237:00 amRNSTransaction in Own Shares
16th Dec 20223:41 pmRNSIssue of Equity
9th Dec 20225:06 pmRNSNet Asset Value(s)
18th Oct 202211:45 amRNSHalf-year Report
21st Sep 20222:34 pmRNSPublication of a Prospectus
31st Aug 20221:11 pmRNSIssue of Equity
29th Jul 202212:05 pmRNSTotal Voting Rights
14th Jul 20222:48 pmRNSRESULTS OF ANNUAL GENERAL MEETING
30th Jun 20222:03 pmRNSIssue of Equity
29th Jun 20222:37 pmRNSDirector Declaration
29th Jun 202211:45 amRNSNet Asset Value(s)
10th Jun 20225:12 pmRNSTransaction in Own Shares
1st Jun 20227:00 amRNSAnnual Financial Report
5th Apr 202212:23 pmRNSIssue of Equity
22nd Mar 20221:40 pmRNSIssue of Equity
1st Feb 20223:59 pmRNSNet Asset Value(s)
17th Dec 20211:08 pmRNSShare allotment and Total Voting Rights
12th Nov 20214:30 pmRNSTransaction in Own Shares
25th Oct 202112:00 pmRNSHalf yearly unaudited financial report
13th Sep 202112:12 pmRNSPublication of a Prospectus
2nd Sep 202110:30 amRNSIssue of Equity
6th Aug 20212:57 pmRNSChange of Registered Office
30th Jul 20211:18 pmRNSIssue of Equity
8th Jul 20215:07 pmRNSResult of Annual General Meeting
30th Jun 20213:38 pmRNSIssue of Equity and Total voting rights
17th Jun 202110:58 amRNSUnaudited Net Asset Value as at 31 May 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.